-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 20, Novartis announced that the new indication of Eltrombopag ethanolamine tablets was approved in China for the treatment of chronic immune (idiopathic) children aged 6-11 who have not responded well to glucocorticoids and immunoglobuli.
Immune thrombocytopenia (ITP), also known as idiopathic thrombocytopenic purpura, is an acquired autoimmune hemorrhagic disease characterized by isolated peripheral blood platelet count reduction without a clear cau.
At present, glucocorticoids and intravenous immune globulin are the first-line therapy for ITP, and thrombopoietic drugs, including recombinant human thrombopoietin (rhTPO), eltrombopag, e.
Novartis Eltrombopag ethanolamine tablets were approved in China in 2017 for adult ITP patients who have not responded well to glucocorticoids, immunoglobulins, e.
In recent years, China has attached great importance to the prevention and treatment of children's blood diseases and malignant tumors, and has issued a series of policies to escort the health of childr.